The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer

Despite the use of front-line anticancer drugs such as paclitaxel for ovarian cancer treatment, mortality rates have remained almost unchanged for the past three decades and the majority of patients will develop recurrent chemoresistant disease which remains largely untreatable. Overcoming chemoresi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Bates, Mark, Spillane, Cathy D., Gallagher, Michael F., McCann, Amanda, Martin, Cara, Blackshields, Gordon, Keegan, Helen, Gubbins, Luke, Brooks, Robert, Brooks, Doug, Selemidis, Stavros, O’Toole, Sharon, O’Leary, John J.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769460/
https://ncbi.nlm.nih.gov/pubmed/33370338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0243715
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars